Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Stage IV pancreatic ductal adenocarcinoma (PDAC) with synchronous liver metastasis: are there survival benefits in liver resection? A systematic review and meta-analysis.
Eur J Surg Oncol
January 2025
Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero Universitaria di Bologna, Italy; Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, S. Orsola-Malpighi Hospital, Italy.
Objective: Metastatic PDAC has a very poor prognosis, and surgery has a limited role. The study aims to evaluate the OS of patients with PDAC and synchronous liver metastasis who undergo surgical therapy (ST) versus non-surgical therapies (NST).
Methods: We performed a random effects meta-analysis.
Unveiling the mystery of hepatic epithelioid angiomyolipoma: A unique case report with literature review.
SAGE Open Med Case Rep
January 2025
Department of Hepatobiliary Pancreatic and Splenic Surgery Ward Ⅰ, The Affiliated ChuZhou Hospital of Anhui Medical University (The First People's Hospital of Chuzhou), ChuZhou, China.
Hepatic epithelioid angiomyolipoma is a rare mesenchymal liver tumor within the perivascular epithelioid cell tumor family, known for its uncertain malignancy and potential for aggressive behavior. Clinical presentation, laboratory findings, and imaging results lack specificity, making pathological examination critical for definitive diagnosis. This case report presents a 61-year-old male patient with a single tumor in the right liver lobe, measuring approximately 101 mm × 99 mm.
View Article and Find Full Text PDFASO Visual Abstract: Hepatectomy with Hepatic Veins Resection and Reconstruction Under Total Vascular Exclusion and Venous Drainage via a Veno-Venous Bypass-An Additional Approach for Complex Hepatectomies.
Ann Surg Oncol
January 2025
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Hépatiques et Digestives, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study.
Sci Rep
January 2025
Department of Urology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, 55 Zhenhai Road, Xiamen, 361003, Fujian Province, China.
In renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus, neoadjuvant therapy could alleviate the burden of tumor thrombus, enhance the safety and feasibility of surgical resection, and improve patient prognosis. The combination of tislelizumab and axitinib has demonstrated efficacy in the treatment of advanced RCC. Our study aimed to evaluate the efficacy and safety in the neoadjuvant therapy setting of tislelizumab and axitinib in RCC patients with IVC tumor thrombus.
View Article and Find Full Text PDFPrediction of early postoperative recurrence of hepatocellular carcinoma by habitat analysis based on different sequence of contrast-enhanced CT.
Front Oncol
January 2025
Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
Aim: To develop a habitat imaging method for preoperative prediction of early postoperative recurrence of hepatocellular carcinoma.
Methods: A retrospective cohort study was conducted to collect data on 344 patients who underwent liver resection for HCC. The internal subregion of the tumor was objectively delineated and the clinical features were also analyzed to construct clinical models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!